The Bottom Line: HypoThermosol allows TIG to increase the stability profile of its clinical cell-based products and extend their shelf-life … the key in the commercial distribution. I have continually … touted BLFS as a “BUY” opportunity. It has enjoyed its recent joys of growth spurts and its sorrow in profit taking by day trader and investors – a market made timing for traders. BLFS closed at $0.30 in a day’s range of $0.30 to $0.30 with only 600 share volume. I continue to reiterate this as a “BUY” on downdraft … still sticking to BLFS being under-valued –with a target of $0.50 by years end since the stock has already visited $0.45 on 11/23/12. I could foresee a $0.05 to $0.10 rise based on the thinly traded activity of the stock many times without a news stimulus.